hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06353477, orgStudyIdInfo id: EOU 2019-10, briefTitle: Hand, Foot, and Mouth Disease: Could EPs®7630 be a Treatment Option, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-06-01, primaryCompletionDateStruct date: 2022-06-01, completionDateStruct date: 2023-01-01, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Eskisehir Osmangazi University, class: OTHER, collaborators name: Abdi Ibrahim Ilac San. ve Tic A.S., descriptionModule briefSummary: This randomized controlled study aims to evaluate the effectiveness and safety of the pharmaceutical extract EPs® 7630 from P.sidoides in treating hand, foot, and mouth disease in children. The study will investigate the impact of EPs® 7630 on the severity of the disease over a specific period and its effects on hospitalization rates and potential complications. This research aims to contribute to the treatment of hand, foot, and mouth disease in children., conditionsModule conditions: Hand, Foot, and Mouth Disease, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: EPs® 7630 is an extract from the roots of Pelargonium sidoides, drug-extract ratio 1 : 8-10, extraction solvent ethanol 11% (w/w). The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \>12 years of age)\] for 7 days and (ii) group 2 (control group) did not receive any herbal medication. The medication was administered orally, at least 30 minutes before or after meals. Patients in both groups were prescribed paracetamol (10 mg/kg/dose, 4 times a day, maximum 4,000 mg/day.) as an antipyretic agent. Temperature measurement was made at home and in the hospital via the axillary route., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 240, type: ACTUAL, armsInterventionsModule interventions name: EPs® 7630, outcomesModule primaryOutcomes measure: the patient's fever status, restlessness, inappetence, and sleeplessness scores, eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 10 Years, stdAges: CHILD, contactsLocationsModule locations facility: Istinye University Medicine Faculty Hospital, city: Esenyurt, state: İstanbul, zip: 34517, country: Turkey, geoPoint lat: 41.02697, lon: 28.67732, hasResults: False
protocolSection identificationModule nctId: NCT06353464, orgStudyIdInfo id: 2306009984, briefTitle: A Translational Understanding of Obesity-Related Phenotypes Using Brain Imaging and Manipulation, acronym: OPBIM, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-04, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2025-09, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Drexel University, class: OTHER, descriptionModule briefSummary: This study will examine a potential relationship between family history of obesity, that is whether people with at least one parent who had obesity in adulthood compared to people with two parents who did not have obesity in adulthood, and the ability of protein intake to curb further intake of food., conditionsModule conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: individuals consume two distinct preloads at separate sessions, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, maskingDescription: Participants consume two preloads one at each visit, but are not informed which preload is being consumed on which test visit., enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Ensure and Water, outcomesModule primaryOutcomes measure: Grams of pizza consumed, primaryOutcomes measure: Baseline medial prefrontal cortex oxygenated hemoglobin, primaryOutcomes measure: Baseline lateral prefrontal cortex oxygenated hemoglobin, primaryOutcomes measure: medial prefrontal cortex Oxygenated hemoglobin concentration, primaryOutcomes measure: lateral prefrontal cortex Oxygenated hemoglobin concentration, secondaryOutcomes measure: medial prefrontal cortex Time to Peak Light Intensity, secondaryOutcomes measure: lateral prefrontal cortex Time to Peak Light Intensity, secondaryOutcomes measure: Preload Oxygenated Hemoglobin Difference, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Drexel University, status: RECRUITING, city: Philadelphia, state: Pennsylvania, zip: 19104, country: United States, contacts name: Principal Investigator, PhD RD, role: CONTACT, phone: 267-359-6287, email: foodbrainstudies@drexel.edu, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06353438, orgStudyIdInfo id: 2024XXXX, briefTitle: Hydraulic Resistance and Older Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: College of Staten Island, the City University of New York, class: OTHER, collaborators name: Bay Ridge Center, descriptionModule briefSummary: The goal of this quasi-experimental study using a pre and post test design is to learn about the effect of participating in an exercise program with hydraulic exercise equipment on fall risk in the older adult population. The main questions it aims to answer are:* Does the use of hydraulic exercise equipment decrease fall risk in older adults?* Does the use of hydraulic exercise equipment improve function in older adults?Participants will be evaluated pre and post intervention for strength, fall risk using Berg Balance Scale, Tinetti Balance and Gait Assessment, Timed Up and Go, and functional ability using the Lower Extremity Functional Scale. Participants will engage in an exercise program using 5 different pieces of hydraulic exercise equipment (Frei FACTUM® novus II line) 2x/week for for 6 weeks for 30-45 minutes each session. The equipment uses concentric movements only and works agonist and antagonist muscles with each machine (IE: push and pull, both concentric)., conditionsModule conditions: Aging, conditions: Fall, conditions: Old Age; Debility, conditions: Muscle Weakness, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Exercise Program, outcomesModule primaryOutcomes measure: Berg Balance Scale, primaryOutcomes measure: Timed Up and Go, primaryOutcomes measure: Tinetti Balance and Gait Assessment Tool, primaryOutcomes measure: Lower Extremity Functional Scale, secondaryOutcomes measure: Strength, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Bay Ridge Center, city: Brooklyn, state: New York, zip: 11209, country: United States, contacts name: Mary Ann Coughlin, role: CONTACT, phone: 718-306-2924, email: mcoughlin@bayridgecenter.org, geoPoint lat: 40.6501, lon: -73.94958, hasResults: False
protocolSection identificationModule nctId: NCT06353425, orgStudyIdInfo id: 0562/66, briefTitle: Multi-country Survey on Violence Against Women Among Women, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Chulalongkorn University, class: OTHER, collaborators name: Asia and Oceania Federation of Obstetrics and Gynaecology, descriptionModule briefSummary: The goal of this observational study is to explore and learn about violence against women (VAW) among reproductive-aged women in Asia and Oceania countries. The main questions it aims to answer are:* pattern and prevalence of VAW among reproductive-aged women* knowledge, attitude, and practice (KAP) towards VAW among reproductive-aged women* the need of support services for VAW among reproductive-aged womenParticipants will be ever-partnered women aged 15-49 years. The definition of "ever-partnered women" included women who have current and former husbands; current and former cohabiting; or non-cohabiting male intimate partners., conditionsModule conditions: Violence Against Women, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 2000, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: prevalence of violence against women, primaryOutcomes measure: KAP towards violence against women, secondaryOutcomes measure: need of support services for violence against women, eligibilityModule sex: FEMALE, minimumAge: 15 Years, maximumAge: 49 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06353412, orgStudyIdInfo id: treatment methods of IIH, briefTitle: Current Treatment Methods of Idiopathic Intracranial Hypertension, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-09-01, completionDateStruct date: 2026-03-09, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Aim of the study :1. to determine the response to each treatment plan.2. to determine when to choose specific treatment method.3. to determine complication of each type of treatment method, conditionsModule conditions: IIH - Idiopathic Intracranial Hypertension, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: Lumbar puncture, outcomesModule primaryOutcomes measure: Patient improvement regarding headache, visual symptoms, primaryOutcomes measure: Patients improvement regarding fundus examination during regular visual assessment, primaryOutcomes measure: Complication, secondaryOutcomes measure: Other, eligibilityModule sex: ALL, minimumAge: 16 Years, maximumAge: 75 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06353399, orgStudyIdInfo id: 23.0366, briefTitle: Guided Bone Regeneration With and Without the Use of Intra-marrow Penetrations, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-15, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: University of Louisville, class: OTHER, descriptionModule briefSummary: The primary aims of this study are to compare, after 6 months, the clinical and histologic results of intra-marrow penetrations vs no intra-marrow penetrations when performing guided bone regeneration procedures., conditionsModule conditions: Ridge Augmentation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: The study involves an investigator (surgeon) and an examiner. The examiner measures the clinical parameters before and after surgery and is blinded to the surgical procedure and if intra-marrow penetrations are utilized., whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Intra-marrow penetrations, interventions name: No Intra-marrow penetrations, outcomesModule primaryOutcomes measure: Alveolar Ridge Width, primaryOutcomes measure: Alveolar Ridge Height, primaryOutcomes measure: Buccal Soft Tissue Thickness, secondaryOutcomes measure: Histomorphometric Measurements, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Louisville, status: RECRUITING, city: Louisville, state: Kentucky, zip: 40202, country: United States, contacts name: Bindu Dukka, BDS, MSD, MPH, role: CONTACT, phone: 502- 852- 1817, email: himabindu.dukka@louisville.edu, contacts name: Niti Patel, DMD, role: CONTACT, phone: 859-685-5423, email: niti.patel@louisville.edu, contacts name: Bindu Dukka, BDS, MSD, MPH, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 38.25424, lon: -85.75941, locations facility: University of Louisville, status: RECRUITING, city: Louisville, state: Kentucky, zip: 40202, country: United States, contacts name: Himabindu Dukka, BDS, MSD, role: CONTACT, geoPoint lat: 38.25424, lon: -85.75941, hasResults: False
protocolSection identificationModule nctId: NCT06353386, orgStudyIdInfo id: 5684-01A, secondaryIdInfos id: MK-5684-01A, type: OTHER, domain: Merck, secondaryIdInfos id: 2023-506288-33, type: REGISTRY, domain: EU CT, secondaryIdInfos id: U1111-1292-6912, type: OTHER, domain: UTN, briefTitle: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-10, primaryCompletionDateStruct date: 2028-03-31, completionDateStruct date: 2028-03-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Merck Sharp & Dohme LLC, class: INDUSTRY, collaborators name: Orion Corporation, Orion Pharma, descriptionModule briefSummary: Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01).The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC.This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for the opevesostat-based treatment combinations. There will be no hypothesis testing in this study., conditionsModule conditions: Prostatic Neoplasms, Castration-Resistant, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 220, type: ESTIMATED, armsInterventionsModule interventions name: Opevesostat, interventions name: Olaparib, interventions name: Docetaxel, interventions name: Cabazitaxel, outcomesModule primaryOutcomes measure: Number of participants who experience one or more dose-limiting toxicities (DLTs), primaryOutcomes measure: Number of participants who experience one or more adverse events (AEs), primaryOutcomes measure: Number of participants who discontinue study intervention due to an AE, primaryOutcomes measure: Prostate-specific antigen (PSA) response rate, secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Radiographic progression-free survival (rPFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Time to first subsequent anticancer therapy (TFST), secondaryOutcomes measure: Time to pain progression (TTPP), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06353373, orgStudyIdInfo id: HZKY-PJ-2024-7, briefTitle: Smart Technology Facilitated Venous Thromboembolism Prophylaxis Based on Bundled Evidence-based Prevention Strategies, acronym: SmaVTE-BEST, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09-01, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-02-28, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Navy General Hospital, Beijing, class: OTHER, descriptionModule briefSummary: Venous thromboembolism (VTE) is the third leading cause of cardiovascular disease deaths globally, and its incidence is increasing over the years. Hospital-acquired VTE accounts for approximately 75% of all deaths attributed to VTE. However, only half of patients with indications for VTE prophylaxis take preventive measures, and high rates of inappropriate VTE prophylaxis prescribing contribute to the gap between VTE prophylaxis and guidelines. To further minimize the gap between clinical practice and guidelines, a range of strategies have been employed across various fields of VTE prophylaxis. One of the most effective measures is the utilization of a Clinical Decision Support System (CDSS). Smart technology-based CDSS facilitates automated evaluation of VTE risk and detection, addressing issues at both the beginning and end of the in-hospital VTE prevention process. but there is still a lack of research on how to effectively implement evidence-based VTE prophylaxis in the middle of the process.In our hospital, routine use of DeVTEcare system (a CDSS for VTE risk assessment and integrated care) for in-hospital management of VTE has been launched since 2021. This study aims to investigate the effect of integrating bundled guideline-based VTE prevention strategies into the DeVTEcare system on in-hospital VTE prophylaxis., conditionsModule conditions: Venous Thromboembolism, conditions: Clinical Decision Support Systems, conditions: Digital Health, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 15626, type: ESTIMATED, armsInterventionsModule interventions name: Application of the modified DeVTEcare system, outcomesModule primaryOutcomes measure: In-hospital VTE, secondaryOutcomes measure: Guideline-compliant prescription of VTE prophylaxis, secondaryOutcomes measure: Preventable VTE, secondaryOutcomes measure: Hospital-related VTE death, secondaryOutcomes measure: Major bleeding, secondaryOutcomes measure: Non-major bleeding, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06353360, orgStudyIdInfo id: HL-06, briefTitle: TTField in Combination With TMZ and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-05, primaryCompletionDateStruct date: 2025-07-15, completionDateStruct date: 2026-03-09, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Jiangsu Healthy Life Innovation Medical Technology Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical trial is To investigate the safety and efficacy of Tumor-Treating Fields (TTFields) in combined with temozolomide (TMZ) and tislelizumab in the treatment of newly diagnosed glioblastoma (GBM)., conditionsModule conditions: Glioblastoma Multiforme, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Tumor Treating Fields, interventions name: Tislelizumab, interventions name: Temozolomide (TMZ), outcomesModule primaryOutcomes measure: Progression-Free Survival (PFS), secondaryOutcomes measure: Number of participants with adverse events (AEs), secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: PFS rate at 6 months, secondaryOutcomes measure: PFS rate at 1 year, secondaryOutcomes measure: OS rate at 1-year, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06353334, orgStudyIdInfo id: 2024-3-22-8, briefTitle: Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Tang Ziren, class: OTHER, descriptionModule briefSummary: Butylphthalide (NBP) is a neuroprotective medication capable of ameliorating neurological dysfunction induced by ischemia, hypoxia, and reperfusion injury in the brain. However, evidence regarding the improvement of neurological function prognosis in patients with return of spontaneous circulation (ROSC) after cardiac arrest (CA) by NBP is limited. This study aims to evaluate the safety and efficacy of NBP treatment in improving the neurological function prognosis of patients with ROSC after CA.The study will be a single-center, randomized, double-blind, placebo-controlled trial. The sample size is estimated to be 100 patients. Eligible patients will be randomly allocated in a 1:1 ratio to receive either NBP or placebo treatment daily for a duration of 14 days. The initial administration of NBP or placebo treatment will commence within 6 hours after ROSC following CA. The primary outcome is the proportion of patients with Cerebral Performance Category (CPC) scores of 1-2 at 90 days after randomization in each group. The primary safety outcome is the percentage of severe adverse events occurring during the 14-day treatment period. This trial will determine the efficacy of NBP in providing neuroprotective effects for patients with ROSC after CA., conditionsModule conditions: Butylphthalide, conditions: Cardiac Arrest, conditions: Neuroprotective Drugs, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Butylphthalide and Sodium Chloride Injection, interventions name: Saline Solution, outcomesModule primaryOutcomes measure: The proportion of patients with a CPC score of 1-2, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Chao-Yang Hospital, city: Beijing, state: Beijing, zip: 100020, country: China, contacts name: Xingsheng Wang, M.D, role: CONTACT, phone: +86 15265386100, email: wangxingsheng1995@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False